235 results
8-K
EX-10.3
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
procedure shall be your sole responsibility.
(c) You may not exercise your option, unless the tax withholding obligations of the Company and/or any
8-K
EX-10.4
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.
(c) You may
8-K
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
to public, private equity backed, and start-up businesses. From 2000 to 2011, Mr. Cohen served in various leadership roles of increasing responsibility
DEFC14A
qrc4a0df5kkia
12 Oct 23
Proxy in contested solicitation
4:22pm
PREC14A
27uwaltktxsxqczddtj
2 Oct 23
Preliminary proxy with contested solicitation
4:49pm
8-K
EX-5.1
p4u0189oizhd6ae f58
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-10.1
zdfgpfw
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-99.1
8rg9k3 tl2qz0ot8
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-1.1
c6hoh
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
424B4
kscrfp8wc6qpyd8
3 Aug 23
Prospectus supplement with pricing info
4:55pm
8-K
EX-10.2
q7rcra0gde8q
24 Jul 23
Entry into a Material Definitive Agreement
4:20pm